Fig. 1: Distribution of different patterns of expression of CD2 and/or CD25 in/on MC in various groups of patients. | Leukemia

Fig. 1: Distribution of different patterns of expression of CD2 and/or CD25 in/on MC in various groups of patients.

From: Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis

Fig. 1

Expression of CD2 and CD25 in or on bone marrow MC was determined by flow cytometry and/or immunohistochemistry in 2225 patients (44.25%) with mastocytosis and available results of CD2 and CD25 expression, including cutaneous mastocytosis (CM, n = 221), indolent systemic mastocytosis (ISM, n = 1595), smoldering systemic mastocytosis (SSM, n = 48), and advanced systemic mastocytosis (advSM, n = 313). In most patients with ISM, MC expressed both CD2 and CD25. However, whereas in a considerable number of patients with SSM and advSM, MC did not express CD2 but still expressed CD25. In very few patients with SM, MC were found to lack CD2 and CD25. MC mast cells.

Back to article page